drug · small molecule
rimegepant sulfate ODT
Marketedupdated 6mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.
targets
Calcitonin gene-related peptide type 1 receptor
all catalysts(10)
approval · 10
Feb 27, 2020
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 18, 2020
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
May 27, 2021
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 8, 2021
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 31, 2022
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Apr 11, 2022
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 12, 2024
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 21, 2025
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 1, 2025
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 16, 2026
approval
$PFE28.06-1.44%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Trials studying rimegepant sulfate ODT
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 25, 2033
~6.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 25, 2039formulationUS 11083724
- Feb 27, 2034compositionUS 8314117
- Feb 25, 2033compositionUS 8759372
News(5)
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetWith 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.biospace · 6d ago
- Pfizer, fresh to China’s obesity market, looks to Viagra model to competePfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.biospace · 15d ago
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 15d ago
- New guidelines on migraine prevention reflect increasing options for patients“There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.stat · 2mo ago
- Biohaven trades cash for ‘upside’ with $795M epilepsy drug dealFaced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.biopharma_dive · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that